CEFTANU-TZ Injection
Ceftazidime 1000 mg + Tazobactam 125 mg
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration.
INDICATIONS
CEFTANU is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:
1.Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coil; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains).
2.Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.;Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).
3.Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coll.
4.Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coil, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).
5.Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains).
6.Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coll.
7.Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant).
8.Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.
DOSAGE AND ADMINISTRATION:
-> Usual recommended dosage: 1 gram IV or IM q8-12hr
-> Uncomplicated urinary tract infections: 250 mg IV or IM q12hr
-> Bone and joint infections: 2 grams IV q12hr
-> Complicated urinary tract infections: 500 mg IV or IM q8-12hr
-> Uncomplicated pneumonia; mild skin and skin-structure infections: 500 mg-1 gram IV or IM q8hr Serious gynecologic and intra-abdominal infections: 2 grams IV q8hr
-> Meningitis: 2 grams IV q8hr
-> Very severe life-threatening infections: 2 grams
-> Lung infections caused by Pseudomonas spp. in 30-50 mg/kg IV to a q8hr patients with cystic fibrosis with normal renal function maximum of 6 grams per day
Neonates (0-4 weeks) 30 mg/kg IV q12hr
Infants and children (1 month-12 years) 30-50 mg/kg IV to a maximum of 6 grams per day q8hr